## Tsutomu Yamazaki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11912470/publications.pdf

Version: 2024-02-01

94 papers 4,916 citations

38 h-index 91712 69 g-index

101 all docs

101 docs citations

times ranked

101

5002 citing authors

#	Article	IF	CITATIONS
1	Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). BMJ Open Diabetes Research and Care, 2021, 9, e001787.	1.2	15
2	Exploring the Competencies of Japanese Expert Nurse Practitioners: A Thematic Analysis. Healthcare (Switzerland), 2021, 9, 1674.	1.0	4
3	Diagnostic Criteria of Flowâ€Mediated Vasodilation for Normal Endothelial Function and Nitroglycerinâ€Induced Vasodilation for Normal Vascular Smooth Muscle Function of the Brachial Artery. Journal of the American Heart Association, 2020, 9, e013915.	1.6	67
4	Usefulness of the SAGE score to predict elevated values of brachial-ankle pulse wave velocity in Japanese subjects with hypertension. Hypertension Research, 2020, 43, 1284-1292.	1.5	6
5	Increased arterial stiffness and cardiovascular risk prediction in controlled hypertensive patients with coronary artery disease: post hoc analysis of FMD-J (Flow-mediated Dilation Japan) Study A. Hypertension Research, 2020, 43, 781-790.	1.5	12
6	Patient-generated health data collection using a wearable activity tracker in cancer patientsâ€"a feasibility study. Supportive Care in Cancer, 2020, 28, 5953-5961.	1.0	20
7	Target of Triglycerides as Residual Risk for Cardiovascular Events in Patients With Coronary Artery Disease 〕 Post Hoc Analysis of the FMD-J Study A ―. Circulation Journal, 2019, 83, 1064-1071.	0.7	17
8	Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension, 2019, 37, 1301-1307.	0.3	8
9	Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). American Journal of Cardiovascular Drugs, 2019, 19, 299-311.	1.0	13
10	Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study. Diabetes, Obesity and Metabolism, 2019, 21, 791-800.	2.2	15
11	Association measures of claims-based algorithms for common chronic conditions were assessed using regularly collected data in Japan. Journal of Clinical Epidemiology, 2018, 99, 84-95.	2.4	33
12	Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care, 2018, 41, 1275-1284.	4.3	43
13	Brachial artery diameter as a marker for cardiovascular risk assessment: FMD-J study. Atherosclerosis, 2018, 268, 92-98.	0.4	26
14	Longitudinal association among endothelial function, arterial stiffness and subclinical organ damage in hypertension. International Journal of Cardiology, 2018, 253, 161-166.	0.8	51
15	Endothelial Dysfunction, Increased Arterial Stiffness, and Cardiovascular Risk Prediction in Patients With Coronary Artery Disease: FMD†(Flowâ€Mediated Dilation Japan) Study A. Journal of the American Heart Association, 2018, 7, .	1.6	84
16	Effects of daily aspirin on cancer incidence and mortality in the elderly Japanese. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 274-281.	1.0	13
17	Cross-sectional and longitudinal associations between serum uric acid and endothelial function in subjects with treated hypertension. International Journal of Cardiology, 2018, 272, 308-313.	0.8	23
18	Endothelial Function Is Impaired in Patients Receiving Antihypertensive Drug Treatment Regardless of Blood Pressure Level. Hypertension, 2017, 70, 790-797.	1.3	27

#	Article	IF	CITATIONS
19	Association Between Waist-to-Height Ratio and Endothelial Dysfunction in Patients With Morbidity ― A Report From the FMD-J Study ―. Circulation Journal, 2017, 81, 1911-1918.	0.7	4
20	Evaluation of human nonmercaptalbumin as a marker for oxidative stress and its association with various parameters in blood. Journal of Clinical Biochemistry and Nutrition, 2017, 61, 79-84.	0.6	18
21	Pancreatic cysts in general population on ultrasonography: Prevalence and development of risk score. Journal of Gastroenterology, 2016, 51, 1133-1140.	2.3	20
22	Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors. Stroke, 2016, 47, 1605-1611.	1.0	27
23	Rationale and Design of the Standard Versus Intensive Statin Therapy for Hypercholesterolemic Patients with Diabetic Retinopathy (EMPATHY) Study: a Randomized Controlled Trial. Journal of Atherosclerosis and Thrombosis, 2016, 23, 976-990.	0.9	22
24	Reliability of measurement of endothelial function across multiple institutions and establishment of reference values in Japanese. Atherosclerosis, 2015, 242, 433-442.	0.4	59
25	Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 Years or Older With Atherosclerotic Risk Factors. JAMA - Journal of the American Medical Association, 2014, 312, 2510.	3.8	257
26	Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry. BMJ Open, 2014, 4, e004760-e004760.	0.8	4
27	Association between the quality of life and asymptomatic episodes of paroxysmal atrial fibrillation in the J-RHYTHM II study. Journal of Cardiology, 2014, 64, 64-69.	0.8	4
28	Prognosis of Myocardial Infarction With Left Ventricular Dysfunction in the Coronary Revascularization Era. Circulation Journal, 2014, 78, 2483-2491.	0.7	12
29	Evaluation of preferable insertion routes for esophagogastroduodenoscopy using ultrathin endoscopes. World Journal of Gastroenterology, 2014, 20, 5045.	1.4	6
30	Changes in serum cholesterol levels determine future risk of cardiovascular events in patients with acute coronary syndrome in the Japanese Coronary Artery Disease (JCAD) Study. Journal of Cardiology, 2013, 61, 387-392.	0.8	4
31	A Multicenter Study Design to Assess the Clinical Usefulness of Semi-Automatic Measurement of Flow-Mediated Vasodilatation of the Brachial Artery. International Heart Journal, 2012, 53, 170-175.	0.5	53
32	Echocardiographic predictors of frequency of paroxysmal atrial fibrillation (AF) and its progression to persistent AF in hypertensive patients with paroxysmal AF: Results from the Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II Study). Heart Rhythm, 2011, 8, 1831-1836.	0.3	21
33	Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the) Tj ETQq1 1 International, 2011, 2, 134-140.	0.784314 i 0.7	gBT /Overloc 24
34	Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study). Europace, 2011, 13, 473-479.	0.7	115
35	Comparison of Antiarrhythmics Used in Patients With Paroxysmal Atrial Fibrillation:. Circulation Journal, 2010, 74, 71-76.	0.7	11
36	Body Size and Atrial Fibrillation in Japanese Outpatients. Circulation Journal, 2010, 74, 66-70.	0.7	24

#	Article	IF	Citations
37	Beta-Blocker Prescription Among Japanese Cardiologists and Its Effect on Various Outcomes. Circulation Journal, 2010, 74, 962-969.	0.7	15
38	Effects of Nicorandil on Cardiovascular Events in Patients With Coronary Artery Disease in The Japanese Coronary Artery Disease (JCAD) Study. Circulation Journal, 2010, 74, 503-509.	0.7	60
39	Impact of Drug Alteration to Maintain Rhythm Control in Paroxysmal Atrial Fibrillation - Subanalysis From J-RHYTHM Study Circulation Journal, 2010, 74, 870-875.	0.7	8
40	Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)—A randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. American Heart Journal, 2010, 159, 361-369.e4.	1.2	19
41	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 2.5mg and Pravastatin10mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-1). Annals of Vascular Diseases, 2009, 2, 148-158.	0.2	1
42	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 5mg and Atorvastatin10mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-2). Annals of Vascular Diseases, 2009, 2, 159-173.	0.2	9
43	Treatment strategy and clinical outcome in Japanese patients with atrial fibrillation. Heart and Vessels, 2009, 24, 287-293.	0.5	17
44	Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: Results from 1-year outcomes in the Japanese REACH Registry. Journal of the Neurological Sciences, 2009, 287, 45-51.	0.3	53
45	Gender Differences in Patients With Coronary Artery Disease in Japan. Circulation Journal, 2009, 73, 912-917.	0.7	8
46	Elevated Serum C-Reactive Protein Levels Predict Cardiovascular Events in the Japanese Coronary Artery Disease (JCAD) Study. Circulation Journal, 2009, 73, 78-85.	0.7	27
47	Optimal Treatment Strategy for Patients With Paroxysmal Atrial Fibrillation J-RHYTHM Study. Circulation Journal, 2009, 73, 242-248.	0.7	198
48	Elevated Serum Uric Acid is an Independent Predictor for Cardiovascular Events in Patients With Severe Coronary Artery Stenosis Subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circulation Journal, 2009, 73, 885-891.	0.7	62
49	Eicosapentaenoic Acid (EPA) in Reducing Secondary Cardiovascular Events in Hypercholesterolemic Japanese Patients. Circulation Journal, 2009, 73, 1197-1198.	0.7	3
50	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 5 mg and Atorvastatin 10 mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-2). Annals of Vascular Diseases, 2009, 2, 159-73.	0.2	5
51	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 2.5 mg and Pravastatin 10 mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-1). Annals of Vascular Diseases, 2009, 2, 148-58.	0.2	0
52	Preoperative disinfection of the conjunctival sac with antibiotics and iodine compounds: A prospective randomized multicenter study. Japanese Journal of Ophthalmology, 2008, 52, 151-161.	0.9	82
53	Demographics and Changes in Medical/Interventional Treatment of Coronary Artery Disease Patients Over a 3.5-Year Period in Japan The Japanese Coronary Artery Disease Study: Trend Examination. Circulation Journal, 2008, 72, 1397-1402.	0.7	8
54	Effects of Medication on Cardiovascular Events in the Japanese Coronary Artery Disease (JCAD) Study. Circulation Journal, 2007, 71, 1835-1840.	0.7	29

#	Article	IF	CITATIONS
55	Prevalence, Awareness and Treatment of Cardiovascular Risk Factors in Patients at High Risk of Atherothrombosis in Japan Results From Domestic Baseline Data of the REduction of Atherotherombosis for Continued Health (REACH) Registry. Circulation Journal, 2007, 71, 995-1003.	0.7	82
56	Proposed New Score to Rate the Strength of Evidence and Its Application to Large-Scale Clinical Trials of Angiotensin-Receptor Blockers. Circulation Journal, 2006, 70, 1155-1158.	0.7	3
57	Randomized Study of Angiotensin II Type 1 Receptor Blocker vs Dihydropiridine Calcium Antagonist for the Treatment of Paroxysmal Atrial Fibrillation in Patients With Hypertension The J-RHYTHM II Study Design for the Investigation of Upstream Therapy for Atrial Fibrillation. Circulation Journal, 2006, 70, 1318-1321.	0.7	16
58	Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1. Biochemical and Biophysical Research Communications, 2004, 322, 310-319.	1.0	64
59	Renoprotective Effect of Losartan in Comparison to Amlodipine in Patients with Chronic Kidney Disease and Hypertension-a Report of the Japanese Losartan Therapy Intended for the Global Renal Protection Hypertensive Patients (JLIGHT) Study. Hypertension Research, 2004, 27, 21-30.	1.5	69
60	Assessment of Acute Myocardial Infarction in Japan by the Japanese Coronary Intervention Study (JCIS) Group. Circulation Journal, 2004, 68, 515-519.	0.7	38
61	Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (ILIGHT) Study. Clinical and Experimental Nephrology. 2003. 7. 221-230.	0.7	22
62	A common lle 823 Met variant of ATP-binding cassette transporter A1 gene (ABCA1) alters high density lipoprotein cholesterol level in Japanese population. Atherosclerosis, 2003, 169, 105-112.	0.4	48
63	Investigation of the Optimal Treatment Strategy for Atrial Fibrillation in Japan-The J-RHYTHM (Japanese) Tj ETQq1	1 8:78431	.4.rgBT /Ove
64	SYSTEMATIZATION OF CRINICAL INFORMATION AND APPLICATION OF ADVANCED INFORMATION TECHNOLOGY TO MEDICAL SAFETY. Sociotechnica, 2003, 1, 383-390.	0.4	1
65	Dual effects of the homeobox transcription factor Csx/Nkx2–5 on cardiomyocytes. Biochemical and Biophysical Research Communications, 2002, 298, 493-500.	1.0	24
66	Continuous Blockade of L-Type Ca2+ Channels Suppresses Activation of Calcineurin and Development of Cardiac Hypertrophy in Spontaneously Hypertensive Rats. Hypertension Research, 2002, 25, 117-124.	1.5	38
67	Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Letters, 2001, 508, 57-60.	1.3	68
68	Left Cervical Aortic Arch With Aortic Coarctation and Saccular Aneurysm. Japanese Circulation Journal, 2000, 64, 544-546.	1.0	15
69	Screening for Cardiac Dysfunction in Asymptomatic Patients by Measuring B-type Natriuretic Peptide Levels International Heart Journal, 2000, 41, 205-214.	0.6	24
70	Context-dependent Transcriptional Cooperation Mediated by Cardiac Transcription Factors Csx/Nkx-2.5 and GATA-4. Journal of Biological Chemistry, 1999, 274, 8231-8239.	1.6	111
71	The Molecular Mechanism of Cardiac Hypertrophy and Failure. Annals of the New York Academy of Sciences, 1999, 874, 38-48.	1.8	41
72	Role of the renin-angiotensin system in cardiac hypertrophy. American Journal of Cardiology, 1999, 83, 53-57.	0.7	83

#	Article	IF	CITATIONS
73	Rho Family Small G Proteins Play Critical Roles in Mechanical Stress–Induced Hypertrophic Responses in Cardiac Myocytes. Circulation Research, 1999, 84, 458-466.	2.0	178
74	Both Gs and Gi Proteins Are Critically Involved in Isoproterenol-induced Cardiomyocyte Hypertrophy. Journal of Biological Chemistry, 1999, 274, 9760-9770.	1.6	139
75	Hypertrophic Responses of Cardiomyocytes Induced by Endothelin-1 through the Protein Kinase C-Dependent but Src and Ras-Independent Pathways Hypertension Research, 1999, 22, 113-119.	1.5	22
76	Signalling Pathways for Cardiac Hypertrophy. Cellular Signalling, 1998, 10, 693-698.	1.7	87
77	Elevated B-type natriuretic peptide levels after anthracycline administration. American Heart Journal, 1998, 136, 362-363.	1.2	157
78	Cell Type–Specific Angiotensin II–Evoked Signal Transduction Pathways. Circulation Research, 1998, 82, 337-345.	2.0	147
79	Role of Ion Channels and Exchangers in Mechanical Stretch–Induced Cardiomyocyte Hypertrophy. Circulation Research, 1998, 82, 430-437.	2.0	154
80	Efficient Inhibition of the Development of Cardiac Remodeling by a Long-Acting Calcium Antagonist Amlodipine. Hypertension, 1998, 31, 32-38.	1.3	30
81	Protein Kinase A and Protein Kinase C Synergistically Activate theRaf-1 Kinase/Mitogen-activated Protein Kinase Cascade in Neonatal Rat Cardiomyocytes. Journal of Molecular and Cellular Cardiology, 1997, 29, 2491-2501.	0.9	42
82	Norepinephrine Induces the $\langle i \rangle$ raf $\langle i \rangle$ -1 Kinase/Mitogen-Activated Protein Kinase Cascade Through Both $\hat{l}_{\pm} \langle sub \rangle$ 1 - and $\hat{l}_{\pm}$ 2-Adrenoceptors. Circulation, 1997, 95, 1260-1268.	1.6	114
83	Reversing Congestive Heart Failure With Endothelin Receptor Antagonists. Circulation, 1997, 95, 1752-1754.	1.6	15
84	Angiotensin II Stimulates c-Jun NH <sub>2</sub> -Terminal Kinase in Cultured Cardiac Myocytes of Neonatal Rats. Circulation Research, 1997, 80, 139-146.	2.0	135
85	Endothelin-1 regulates normal cardiovascular development and cardiac cellular hypertrophy. Journal of Cardiac Failure, 1996, 2, S7-S12.	0.7	7
86	Activation of p70 S6 protein kinase is necessary for angiotensin II-induced hypertrophy in neonatal rat cardiac myocytes. FEBS Letters, 1996, 379, 255-259.	1.3	47
87	Protein Kinase C, but Not Tyrosine Kinases or Ras, Plays a Critical Role in Angiotensin Il-induced Activation of Raf-1 Kinase and Extracellular Signal-regulated Protein Kinases in Cardiac Myocytes. Journal of Biological Chemistry, 1996, 271, 33592-33597.	1.6	196
88	Mechanical stretch activates the stressâ€activated protein kinase in cardiac myocytes. FASEB Journal, 1996, 10, 631-636.	0.2	226
89	Molecular aspects of mechanical stress-induced cardiac hypertrophy. Molecular and Cellular Biochemistry, 1996, 163-164, 197-201.	1.4	23
90	Endothelin-1 Is Involved in Mechanical Stress-induced Cardiomyocyte Hypertrophy. Journal of Biological Chemistry, 1996, 271, 3221-3228.	1.6	315

#	Article	IF	CITATIONS
91	Molecular Cloning and Characterization of Human Cardiac Homeobox Gene <i>CSX1</i> . Circulation Research, 1996, 79, 920-929.	2.0	66
92	Angiotensin II Partly Mediates Mechanical Stress–Induced Cardiac Hypertrophy. Circulation Research, 1995, 77, 258-265.	2.0	244
93	Molecular Aspects of the Control of Myocardial Relaxation. , 1994, , 25-32.		3
94	Experimental Studies on the Mechanism of Sound Couduction of the Ossicular Chain. Audiology, 1967, 10, 5-15.	0.0	O